Market Capitalization of J K Pharmachem Ltd
J K Pharmachem Ltd
NSE: JKPHARMA
Market Cap
Key Highlights
- The Market Cap of J K Pharmachem Ltd is ₹ 11.22 crore as of 08 Sep 06 .
J K Pharmachem Ltd
NSE: JKPHARMA
Share Price
Market Price of J K Pharmachem Ltd
1M
1Y
3Y
5Y
Last Ten Days Market Price
| Date | |
|---|---|
| 08 Sep 2006 | 1.79 |
| 07 Sep 2006 | 1.82 |
| 06 Sep 2006 | 1.83 |
| 05 Sep 2006 | 1.9 |
| 04 Sep 2006 | 1.86 |
| 01 Sep 2006 | 1.78 |
| 31 Aug 2006 | 1.79 |
| 30 Aug 2006 | 1.77 |
| 29 Aug 2006 | 1.85 |
| 28 Aug 2006 | 1.94 |
BlinkX Score for J K Pharmachem Ltd
Asset Value vs Market Value of J K Pharmachem Ltd
Market Value
₹ 0
Asset Value
₹ 0
* All values are in ₹ crores
Competitive Comparison of Market Cap
Key Valuation Metric of J K Pharmachem Ltd
Historical P/E Ratio of J K Pharmachem Ltd
The price-to-earnings ratio (P/E ratio) is a valuation measure calculated by dividing a company's current share price by its earnings per share. P/E Ratio Formula P/E ratio = (CMP of share/ Earning per share) Types of Price to Earning Ratio 1. Forward P/E ratio: It is calculated by simply dividing the price of a single unit of a company along with the estimated earnings of a company derived from its future earning guidance. 2. Trailing P/E ratio: It is the most common metric used by investors where past earnings of a company over a period are considered.
Historical P/E Ratio of J K Pharmachem Ltd
Historical Revenue of J K Pharmachem Ltd
Revenue term means the amount of money a company earns from its primary business activities such as the sales of its products & services.\r\r\n\r\r\nTypes of Revenue:\r\r\n\r\r\n1. Operating revenue: It refers to the income generated from the core business activities, which are sales of goods or services rendered.\r\r\n\r\r\n2. Non-Operating revenue: It is the income generated from secondary sources unrelated to the primary business. Examples include rents, dividends, interest, and royalty fees.\r\r\n\r\r\nFormula for Revenue:\r\r\n\r\r\nThe formula for calculating revenue is based on two goods & services:\r\r\n\r\r\nFor goods:\r\r\nRevenue = Avg unit price x Number of Units sold\r\r\n\r\r\nFor services:\r\r\nRevenue = Avg unit price x Number of Customers served.
Historical Revenue of J K Pharmachem Ltd
Historical EBITDA of J K Pharmachem Ltd
PBIDT stands for Profit Before Interest, Depreciation, and Taxes. It is a financial metric that measures a company's profitability before accounting for interest expenses, depreciation of assets, and taxes. Formula to calculate PBIDT: PBIDT = Net Income + Interest + Depreciation + Taxes or PBIDT = Operating Income + Depreciation + Taxes PBIDT vs EBITDA vs EBIT vs EBT: Here is a brief explanation of the differences: - PBIDT (Profit Before Interest, Depreciation, and Taxes) includes taxes in its calculation, unlike EBITDA. - EBITDA (Earnings Before Interest, Taxes, Depreciation, and Amortization) excludes taxes and interest, focusing on operational performance. - EBIT (Earnings Before Interest and Taxes) excludes interest and taxes, providing a measure of core operational profitability. - EBT (Earnings Before Taxes) includes all operating income but does not account for interest expenses. Conclusion: PBIDT, similar to EBITDA, is a measure of operational profitability but includes taxes in its calculation.
Historical EBITDA of J K Pharmachem Ltd
Historical Net Profit of J K Pharmachem Ltd
Net profit is the amount of money a company retains after accounting for all expenses, depreciation, interest, taxes, and other deductions.\r\r\n\r\r\nNet Profit formula is expressed as:\r\r\n\r\r\nNet Profit = Total Revenue - Total Expense\r\r\n\r\r\nNet Profit Margin Ratio:\r\r\n\r\r\nNet Profit Margin Ratio = Net Profit / Total Revenue
Historical Net Profit of J K Pharmachem Ltd
Dividend Payout Over Time
About J K Pharmachem Ltd
- Jointly promoted by J K Industries and TIDCO, J K Pharmachem manufactures drugs and pharmaceuticals.
- It entered the capital market in Oct.'94 to part-finance the setting up of a plant to manufacture 1250 MMU P.a of pencillin-G, based on a microbial strain from the technical collaborators -- IGC (Cyprus), Cyprus -- a wholly-owned subsidiary of ICN Galenika.
- Commercial production at this plant commenced in Oct.'95. The company has a tie-up with ICN Galenika, part of the ICN Pharmaceuticals group (one of the pioneering manufacturers of pencillin-G), to set up a 1250-mmu capacity plant. It has already produced international standard penicillin with Indian raw materials, at its collaborator's plant which is among the best in the world.
- In addition, J K Pharmachem had set-up its own R&D activity well in advance for future development in the field of bio-technology.
